ARCUTIS BEGINS ENROLLING PHASE 3 STUDY EVALUATING ZORYVE® (ROFLUMILAST) CREAM 0.3% IN MODERATE TO SEVERE ATOPIC DERMATITIS

Reuters · 3d ago

Please log in to view news